Nico Löchner

German Federal Government invests 300 Million Euros in CureVac tinyurl.com/y7kxpqe4

$FGEN Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease prnewswire.com/news-releases/…

$STML MENARINI GROUP TO ACQUIRE STEMLINE THERAPEUTICS TOTAL POTENTIAL CONSIDERATION OF $12.50 PER SHARE COMPRISING $11.50 CASH AND $1.00 CONTINGENT VALUE RIGHT

$AFMD Affimed Mourns Passing of Chief Financial Officer Dr. Florian Fischer affimed.com/affimed-mourns…

$AFMD Affimed Announces Appointment of Andreas Harstrick, M.D., as Chief Medical Officer

$BPMC LEERINK RAISES TARGET PRICE TO $120 FROM $103

$FGEN PR FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease globenewswire.com/news-release/2…

$FGEN -In incident dialysis patients, roxadustat had a lower risk of MACE and MACE+ and showed a trend towards lower risk of all-cause mortality relative to epoetin alfa

$FGEN -Dialysis-dependent patients receiving roxadustat had a lower risk of MACE+ and no increased risk of MACE or all-cause mortality versus epoetin alfa

$FGEN -In non dialysis-dependent patients receiving roxadustat, the risk of MACE, MACE+ and all-cause mortality was comparable to placebo

$FGEN Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy and No Increased Cardiovascular Risk in Patients with Anemia from Chronic Kidney Disease Versus Comparators businesswire.com/news/home/2019…

$FGEN

$FGEN halted

$MDCO ORION-11 STUDY MET ALL PRIMARY AND SECONDARY EFFICACY ENDPOINTS WITH EFFICACY CONSISTENT WITH PHASE 1 AND 2 STUDIES

$AFMD Investigating Safety And Preliminary Efficacy Of Afm13 Plus Pembrolizumab In Patients With Relapsed/Refractory Hodgkin Lymphoma After Brentuximab Vedotin Failure onlinelibrary.wiley.com/doi/10.1002/ho…

$AFMD decides to terminate AFM11 T cell engager Phase 1 program

$FGEN $AZN roxadustat Q2'19 anaemia of CKD: data readout (pooled safety) H2'19: anaemia of CKD: regulatory submission (US) 2020: anaemia of myelodysplastic syndrome: data readout astrazeneca.com/content/dam/az…

$HSGX Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics

$ALNY $REGN Regeneron to Invest $800 million Through Upfront Cash and Equity Investment in Alnylam, with up to Additional $200 Million in Potential Near-Term Milestones

$ALNY Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases